[Federal Register Volume 61, Number 113 (Tuesday, June 11, 1996)]
[Rules and Regulations]
[Pages 29479-29480]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-14646]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
21 CFR Part 522
Implantation or Injectable Dosage Form New Animal Drugs;
Trenbolone Acetate and Estradiol
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect approval of a supplemental new animal drug
application (NADA) filed by Roussel-UCLAF, Division Agro-Veterinaire.
The supplemental NADA provides for use of an ear implant containing
trenbolone acetate and estradiol in pasture steers for increased rate
of weight gain.
EFFECTIVE DATE: June 11, 1996.
FOR FURTHER INFORMATION CONTACT: Jack Caldwell, Center for Veterinary
Medicine (HFV-126), Food and Drug
[[Page 29480]]
Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0217.
SUPPLEMENTARY INFORMATION: Roussel-UCLAF, Division Agro-Veterinaire,
163 Ave. Gambetta, 75020 Paris, France, filed supplemental NADA 140-
897, which provides for use of an ear implant containing 2 pellets,
each pellet containing 20 milligrams (mg) of trenbolone acetate and 4
mg of estradiol. The implant is used in pasture steers (slaughter,
stocker, feeder) for increased rate of weight gain. The supplemental
NADA is approved as of March 27, 1996, and the regulations are amended
in 21 CFR 522.2477 by adding new paragraph (c)(3) to reflect the
approval. The basis for approval is discussed in the freedom of
information summary.
In accordance with the freedom of information provisions of part 20
(21 CFR part 20) and Sec. 514.11(e)(2)(ii) (21 CFR 514.11 (e)(2)(ii)),
a summary of safety and effectiveness data and information submitted to
support approval of this application may be seen in the Dockets
Management Branch (HFA-305), Food and Drug Administration, 12420
Parklawn Dr., rm. 1-23, Rockville, MD 20857, between 9 a.m. and 4 p.m.,
Monday through Friday.
Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), this approval qualifies
for a 3-year period of marketing exclusivity beginning on March 27,
1996, because new clinical or field investigations (other than
bioequivalence or residue studies) essential to the approval were
conducted or sponsored by the applicant.
The agency has carefully considered the potential environmental
effects of this action. FDA has concluded that the action will not have
a significant impact on the human environment, and that an
environmental impact statement is not required. The agency's finding of
no significant impact and the evidence supporting that finding,
contained in an environmental assessment, may be seen in the Dockets
Management Branch (address above) between 9 a.m. and 4 p.m., Monday
through Friday.
List of Subjects in 21 CFR Part 522
Animal drugs.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is
amended as follows:
PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
1. The authority citation for 21 CFR part 522 continues to read as
follows:
Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 360b).
2. Section 522.2477 is amended by adding new paragraph (c)(3) to
read as follows:
Sec. 522.2477 Trenbolone acetate and estradiol.
* * * * *
(c) * * *
(3) Pasture steers (slaughter, stocker, and feeder steers). (i)
Amount. 40 milligrams of trenbolone acetate and 8 milligrams of
estradiol (2 pellets, each pellet containing 20 milligrams of
trenbolone acetate and 4 milligrams of estradiol) per animal.
(ii) Indications for use. For increased rate of weight gain.
(iii) Limitations. Implant subcutaneously in ear only.
Dated: May 17, 1996.
Robert C. Livingston,
Director, Office of New Animal Drug Evaluation, Center for Veterinary
Medicine.
[FR Doc. 96-14646 Filed 6-10-96; 8:45 am]
BILLING CODE 4160-01-F